Company intelligence / Profile preview

REPRESPLA

Yokohama, Kanagawa, Japandnb.com ↗

Ownership: Private
Development stage: Other

Overview

REPROCELL’s partner Steminent Biotherapeutics reported positive Phase II results in Taiwan and Japan for "Stemchymal®" in spinocerebellar ataxia. Gameto’s Fertilo program using REPROCELL’s iPSCs has FDA IND clearance and entered U.S. Phase 3 trials. The company provides GMP-compliant manufacturing of hiPSC and hMSC products, with a focus on regenerative medicine therapies targeting neurodegenerative diseases.

Therapeutic areas: NeurologyWomen's Health
Modalities: Induced pluripotent stem cell derived therapyMesenchymal stem cell therapyGene therapy (CRISPR-based)Small molecule (in drug discovery support)mRNA-based drugs (support for iPSC generation)Exosome-based therapy (research support)
Industry: Drug Discovery Services

Partnerships

Steminent Biotherapeutics Inc.Gameto Inc.

Beyond the preview

Go deeper on REPRESPLA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REPRESPLA.

Explore the full profile